Flow Neuroscience announced that the FDA approved its Flow at-home brain stimulation device for treating major depressive disorder (MDD).

The FDA has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to ...

The FDA has approved a device that aims to treat depression by sending electric current into a part of the brain known to ...

The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for ...

Biohaven said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory setbacks for the drugmaker this year. The ...

The FDA has approved Transcranial Magnetic Stimulation (TMS), a non-drug, magnetic pulse device, for use in teens as young as 15 to treat severe depression. TMS is now an option for adolescents who ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...

SAN FRANCISCO, California -- For the first time, the FDA has approved a medication specifically to treat new mothers who suffer from postpartum depression. The drug is called Brexanolone and will be ...

Flow Neuroscience has secured FDA approval for its at-home brain stimulation device, the FL-100 wearable device, as a ...